RLAY
Relay Therapeutics, Inc.$18.95-0.10 (-0.55%)Prev Close$19.06·MCap$4.14B·P/E—·Vol2.01M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
30
$127.02M
◆
Net Activity
Net Seller
$127.02M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Relay Therapeutics, Inc. (RLAY) has been exclusively selling, with 0 insider purchases totaling $0.00 and 30 insider sales totaling $127.02M. The most recent insider transaction was by Bergstrom Donald A (officer: President, R&D), who sold $161.8K worth of shares on Sep 9, 2026. Relay Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.14B.
RLAY Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 8,530 | $18.97 | $161.8K | 399,130 |
| Sep 9, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $18.94 | $335.6K | 122,851 |
| Sep 9, 2026 | Patel Sanjiv | director, officer: President and CEO | Sell | 48,199 | $18.94 | $912.9K | 519,500 |
| Aug 28, 2026 | Rahmer Peter | officer: See remarks | Sell | 4,508 | $20.03 | $90.3K | 223,657 |
| Aug 28, 2026 | SVF Pauling (Cayman) Ltd | 10 percent owner | Sell | 6,000,000 | $19.40 | $116.40M2.7% OS | 21,904,964 |
| Aug 18, 2026 | Patel Sanjiv | director, officer: President and CEO | Sell | 48,199 | $20.33 | $979.9K | 567,699 |
| Aug 18, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $19.74 | $349.7K | 140,568 |
| Jul 30, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 2,237 | $18.61 | $41.6K | 407,660 |
| Jul 30, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 1,459 | $18.61 | $27.2K | 158,285 |
| Jul 30, 2026 | Rahmer Peter | officer: See remarks | Sell | 748 | $18.61 | $13.9K | 228,165 |
| Jul 8, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 8,660 | $18.71 | $162.0K | 409,897 |
| Jul 8, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $18.69 | $331.1K | 159,744 |
| Jul 8, 2026 | Patel Sanjiv | director, officer: President and CEO | Sell | 48,199 | $19.58 | $943.7K | 615,898 |
| Jul 2, 2026 | Rahmer Peter | officer: See remarks | Sell | 50,000 | $19.09 | $954.5K | 225,857 |
| Jun 24, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 93,456 | $16.94 | $1.58M | 418,557 |
| Jun 24, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 69,277 | $16.98 | $1.18M | 177,461-28% |
| May 14, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $12.86 | $227.8K | 195,178 |
| Apr 30, 2026 | Rahmer Peter | officer: See remarks | Sell | 753 | $14.79 | $11.1K | 275,857 |
| Apr 30, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 972 | $14.79 | $14.4K | 212,895 |
| Apr 30, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 1,490 | $14.79 | $22.0K | 418,557 |
| Apr 9, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 19,517 | $13.19 | $257.5K | 213,867 |
| Mar 11, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $10.06 | $178.2K | 231,584 |
| Jan 27, 2026 | Bergstrom Donald A | President, R&D | Sell | 21,581 | $7.72 | $166.7K | 0 |
| Jan 27, 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | 15,515 | $7.71 | $119.6K | 0 |
| Jan 27, 2026 | Rahmer Peter | See remarks | Sell | 13,038 | $7.71 | $100.5K | 0 |
| Jan 6, 2026 | Patel Sanjiv | President and CEO | Sell | 43,168 | $7.82 | $337.6K | 0 |
| Nov 3, 2025 | Patel Sanjiv | President and CEO | Sell | 62,073 | $7.00 | $434.5K | 0 |
| Oct 28, 2025 | Bergstrom Donald A | President, R&D | Sell | 30,897 | $7.29 | $225.2K | 0 |
| Oct 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 21,664 | $7.29 | $157.9K | 0 |
| Oct 28, 2025 | Rahmer Peter | See remarks | Sell | 40,529 | $7.40 | $299.9K | 0 |
| Jul 28, 2025 | Adams Brian | Chief Legal Officer | Sell | 19,913 | $3.68 | $73.4K | 0 |
| Jul 28, 2025 | Bergstrom Donald A | President, R&D | Sell | 30,770 | $3.69 | $113.5K | 0 |
| Jul 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 20,081 | $3.69 | $74.0K | 0 |
| Jul 28, 2025 | Rahmer Peter | See remarks | Sell | 17,083 | $3.68 | $62.9K | 0 |
| Jul 9, 2025 | Patel Sanjiv | President and CEO | Sell | 61,379 | $3.57 | $219.1K | 0 |
| Apr 28, 2025 | Adams Brian | Chief Legal Officer | Sell | 1,644 | $3.17 | $5.2K | 0 |
| Apr 28, 2025 | Bergstrom Donald A | President, R&D | Sell | 31,562 | $3.02 | $95.4K | 0 |
| Apr 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 19,191 | $3.07 | $58.8K | 0 |
| Apr 28, 2025 | Rahmer Peter | See remarks | Sell | 12,103 | $3.02 | $36.5K | 0 |
| Apr 23, 2025 | Patel Sanjiv | President and CEO | Sell | 61,422 | $2.97 | $182.4K | 0 |
| Mar 27, 2025 | Bergstrom Donald A | President, R&D | Sell | 986 | $2.84 | $2.8K | 0 |
| Mar 27, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 4,864 | $2.84 | $13.8K | 0 |
| Mar 27, 2025 | Rahmer Peter | See remarks | Sell | 247 | $2.84 | $701.48 | 0 |
| Feb 13, 2025 | Patel Sanjiv | President and CEO | Sell | 215,506 | $3.80 | $818.4K | 883,089 |
| Jan 30, 2025 | Adams Brian | Chief Legal Officer | Sell | 54,479 | $4.55 | $247.9K | 406,270 |
| Jan 30, 2025 | Bergstrom Donald A | President, R&D | Sell | 80,450 | $4.50 | $362.3K | 646,861 |
| Jan 30, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 58,936 | $4.55 | $268.3K | 400,222 |
| Jan 30, 2025 | Rahmer Peter | See remarks | Sell | 45,464 | $4.50 | $204.8K | 419,681 |
| Jan 23, 2025 | Patel Sanjiv | President and CEO | Sell | 375,000 | $4.70 | $1.76M | 449,548-45% |
| Jan 6, 2025 | Rahmer Peter | See remarks | Sell | 80,909 | $4.27 | $345.6K | 357,507 |
Showing 1–50 of 187
1 / 4
RLAY Insider Buying Activity
The following table shows recent insider purchases of Relay Therapeutics, Inc. (RLAY) stock reported via SEC Form 4 filings.
No insider buying activity found for RLAY in the last 12 months.
RLAY Insider Selling Activity
The following table shows recent insider sales of Relay Therapeutics, Inc. (RLAY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 8,530 | $18.97 | $161.8K | 399,130 |
| Sep 9, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $18.94 | $335.6K | 122,851 |
| Sep 9, 2026 | Patel Sanjiv | director, officer: President and CEO | Sell | 48,199 | $18.94 | $912.9K | 519,500 |
| Aug 28, 2026 | Rahmer Peter | officer: See remarks | Sell | 4,508 | $20.03 | $90.3K | 223,657 |
| Aug 28, 2026 | SVF Pauling (Cayman) Ltd | 10 percent owner | Sell | 6,000,000 | $19.40 | $116.40M2.7% OS | 21,904,964 |
| Aug 18, 2026 | Patel Sanjiv | director, officer: President and CEO | Sell | 48,199 | $20.33 | $979.9K | 567,699 |
| Aug 18, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $19.74 | $349.7K | 140,568 |
| Jul 30, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 2,237 | $18.61 | $41.6K | 407,660 |
| Jul 30, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 1,459 | $18.61 | $27.2K | 158,285 |
| Jul 30, 2026 | Rahmer Peter | officer: See remarks | Sell | 748 | $18.61 | $13.9K | 228,165 |
| Jul 8, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 8,660 | $18.71 | $162.0K | 409,897 |
| Jul 8, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $18.69 | $331.1K | 159,744 |
| Jul 8, 2026 | Patel Sanjiv | director, officer: President and CEO | Sell | 48,199 | $19.58 | $943.7K | 615,898 |
| Jul 2, 2026 | Rahmer Peter | officer: See remarks | Sell | 50,000 | $19.09 | $954.5K | 225,857 |
| Jun 24, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 93,456 | $16.94 | $1.58M | 418,557 |
| Jun 24, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 69,277 | $16.98 | $1.18M | 177,461-28% |
| May 14, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $12.86 | $227.8K | 195,178 |
| Apr 30, 2026 | Rahmer Peter | officer: See remarks | Sell | 753 | $14.79 | $11.1K | 275,857 |
| Apr 30, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 972 | $14.79 | $14.4K | 212,895 |
| Apr 30, 2026 | Bergstrom Donald A | officer: President, R&D | Sell | 1,490 | $14.79 | $22.0K | 418,557 |
| Apr 9, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 19,517 | $13.19 | $257.5K | 213,867 |
| Mar 11, 2026 | Catinazzo Thomas | officer: Chief Financial Officer | Sell | 17,717 | $10.06 | $178.2K | 231,584 |
| Jan 27, 2026 | Bergstrom Donald A | President, R&D | Sell | 21,581 | $7.72 | $166.7K | 0 |
| Jan 27, 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | 15,515 | $7.71 | $119.6K | 0 |
| Jan 27, 2026 | Rahmer Peter | See remarks | Sell | 13,038 | $7.71 | $100.5K | 0 |
| Jan 6, 2026 | Patel Sanjiv | President and CEO | Sell | 43,168 | $7.82 | $337.6K | 0 |
| Nov 3, 2025 | Patel Sanjiv | President and CEO | Sell | 62,073 | $7.00 | $434.5K | 0 |
| Oct 28, 2025 | Bergstrom Donald A | President, R&D | Sell | 30,897 | $7.29 | $225.2K | 0 |
| Oct 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 21,664 | $7.29 | $157.9K | 0 |
| Oct 28, 2025 | Rahmer Peter | See remarks | Sell | 40,529 | $7.40 | $299.9K | 0 |
| Jul 28, 2025 | Adams Brian | Chief Legal Officer | Sell | 19,913 | $3.68 | $73.4K | 0 |
| Jul 28, 2025 | Bergstrom Donald A | President, R&D | Sell | 30,770 | $3.69 | $113.5K | 0 |
| Jul 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 20,081 | $3.69 | $74.0K | 0 |
| Jul 28, 2025 | Rahmer Peter | See remarks | Sell | 17,083 | $3.68 | $62.9K | 0 |
| Jul 9, 2025 | Patel Sanjiv | President and CEO | Sell | 61,379 | $3.57 | $219.1K | 0 |
| Apr 28, 2025 | Adams Brian | Chief Legal Officer | Sell | 1,644 | $3.17 | $5.2K | 0 |
| Apr 28, 2025 | Bergstrom Donald A | President, R&D | Sell | 31,562 | $3.02 | $95.4K | 0 |
| Apr 28, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 19,191 | $3.07 | $58.8K | 0 |
| Apr 28, 2025 | Rahmer Peter | See remarks | Sell | 12,103 | $3.02 | $36.5K | 0 |
| Apr 23, 2025 | Patel Sanjiv | President and CEO | Sell | 61,422 | $2.97 | $182.4K | 0 |
| Mar 27, 2025 | Bergstrom Donald A | President, R&D | Sell | 986 | $2.84 | $2.8K | 0 |
| Mar 27, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 4,864 | $2.84 | $13.8K | 0 |
| Mar 27, 2025 | Rahmer Peter | See remarks | Sell | 247 | $2.84 | $701.48 | 0 |
| Feb 13, 2025 | Patel Sanjiv | President and CEO | Sell | 215,506 | $3.80 | $818.4K | 883,089 |
| Jan 30, 2025 | Adams Brian | Chief Legal Officer | Sell | 54,479 | $4.55 | $247.9K | 406,270 |
| Jan 30, 2025 | Bergstrom Donald A | President, R&D | Sell | 80,450 | $4.50 | $362.3K | 646,861 |
| Jan 30, 2025 | Catinazzo Thomas | Chief Financial Officer | Sell | 58,936 | $4.55 | $268.3K | 400,222 |
| Jan 30, 2025 | Rahmer Peter | See remarks | Sell | 45,464 | $4.50 | $204.8K | 419,681 |
| Jan 23, 2025 | Patel Sanjiv | President and CEO | Sell | 375,000 | $4.70 | $1.76M | 449,548-45% |
| Jan 6, 2025 | Rahmer Peter | See remarks | Sell | 80,909 | $4.27 | $345.6K | 357,507 |
RLAY Insiders
Similar Stocks to RLAY
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B